Laboratory Corporation of America Holdings Stock

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-05-16 pm EDT 5-day change 1st Jan Change
213.1 USD -0.04% Intraday chart for Laboratory Corporation of America Holdings +3.39% -6.23%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 12.81B Sales 2025 * 13.43B Capitalization 17.97B
Net income 2024 * 982M Net income 2025 * 1.11B EV / Sales 2024 * 1.78 x
Net Debt 2024 * 4.84B Net Debt 2025 * 3.97B EV / Sales 2025 * 1.63 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
16.3 x
Employees 61,975
Yield 2024 *
1.38%
Yield 2025 *
1.41%
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy MT
US FDA publishes final rule for laboratory developed tests RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 MT
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating MT
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225 MT
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating MT
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated MT
More news

Latest transcript on Laboratory Corporation of America Holdings

1 day-0.04%
1 week+5.71%
Current month+5.84%
1 month+4.82%
3 months-4.05%
6 months+1.53%
Current year-6.23%
More quotes
1 week
205.46
Extreme 205.46
215.07
1 month
196.11
Extreme 196.11
215.07
Current year
196.11
Extreme 196.11
234.09
1 year
195.01
Extreme 195.01
243.30
3 years
195.01
Extreme 195.01
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.61
Extreme 95.61
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13-03-31
Director of Finance/CFO 63 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Chief Executive Officer 58 13-03-31
Director/Board Member 68 12-12-31
Director/Board Member 66 06-05-16
More insiders
Date Price Change Volume
24-05-16 213.1 -0.04% 676,626
24-05-15 213.2 +0.95% 542,275
24-05-14 211.2 +0.39% 536,448
24-05-13 210.4 +1.30% 792,854
24-05-10 207.7 +0.74% 722,931

Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT

More quotes
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
213.2 USD
Average target price
239.6 USD
Spread / Average Target
+12.38%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW